|1.||Fraga, Carlos A M: 3 articles (10/2015 - 03/2008)|
|2.||Barreiro, Eliezer J: 3 articles (10/2015 - 03/2008)|
|3.||Noël, François: 2 articles (10/2015 - 01/2013)|
|4.||Betti, Andresa H: 2 articles (01/2013 - 03/2008)|
|5.||Neves, Gilda: 2 articles (01/2013 - 03/2008)|
|6.||Rates, Stela M K: 2 articles (01/2013 - 03/2008)|
|7.||Pompeu, Thais Emanoelle T: 1 article (10/2015)|
|8.||Menegatti, Ricardo: 1 article (10/2015)|
|9.||Monteiro do Monte, Fernando: 1 article (10/2015)|
|10.||Bosier, Barbara: 1 article (10/2015)|
|1.||Schizophrenia (Dementia Praecox)
10/01/2015 - "These two characteristics could contribute to the atypical-like profile observed after administration of LASSBio-579 to rodents, in models of positive and negative symptoms of schizophrenia. "
01/15/2013 - "In summary, our results characterize LASSBio-579 as a multi-target ligand active in pharmacological animal models of schizophrenia, confirming that this compound could be included in development programs aiming at a new drug for treating schizophrenia."
01/15/2013 - "New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia."
03/01/2008 - "Previous studies have demonstrated that LASSBio-579 and LASSBio-581, two N-phenylpiperazine derivatives designed for the treatment of schizophrenia, are presynaptic dopamine D(2) receptor agonists that induce a hypothermic effect in mice that is not mediated by dopamine receptor activation. "
01/15/2013 - "LASSBio-579 also induced a motor impairment, catalepsy and a mild sedative effect but only at doses 3-120 times higher than those with antipsychotic-like effects. "
01/15/2013 - "In addition, LASSBio-579 (0.5 and 1 mg/kg p.o.) reversed the catalepsy induced by WAY 100,635, corroborating its action on both dopaminergic and serotonergic neurotransmission and pointing to the contribution of 5-HT(1A) receptor activation to its pharmacological profile. "
01/15/2013 - "Moreover, co-administration of sub-effective doses of LASSBio-579 with sub-effective doses of clozapine or haloperidol prevented the apomorphine-induced climbing without induction of catalepsy. "
|2.||Dopamine Receptors (Dopamine Receptor)
|5.||5-HT1A Serotonin Receptor